Dupilumab for cancer-associated refractory pruritus

Dupilumab for cancer-associated refractory pruritus

Background: Pruritus can be an intolerable symptom in patients with cancer. Type 2 inflammation, and specifically, the cytokines IL-4, IL-13, and IL-31, play major roles in the itching process. Dupilumab is an antibody against IL-4Rα, which is a common IL-4 and IL-13 receptor subunit. Blocking IL-4...

Täydet tiedot

Bibliografiset tiedot
Päätekijät: Aviv Talmon, MD, Shlomo Elias, MD, PhD, Limor Rubin, MD, Yaarit Ribak, MD, Eyal Ben Dori, MD, Oded Shamriz, MD, Michal Lotem, MD, Irit Adini, PhD, Yuval Tal, MD, PhD
Aineistotyyppi: Artikkeli
Kieli:English
Julkaistu: Elsevier 2023-08-01
Sarja:Journal of Allergy and Clinical Immunology: Global
Aiheet:
Oncologic pruritus
chronic pruritus
itch
IL-4
IL-13
IL-31
Linkit:http://www.sciencedirect.com/science/article/pii/S277282932300053X

Internet

http://www.sciencedirect.com/science/article/pii/S277282932300053X

Samankaltaisia teoksia